0 Items
Select Page

Vaccinia

Vaccinia virus is known for its use in smallpox vaccination, but following the eradication of smallpox, routine vaccination is no-longer performed. Recent interest in Vaccinia has centred on its potential use as a vector for immunization against other viruses, with a focus on developing less virulent strains than those used for vaccination against smallpox.

The Native Antigen Company offers a recombinant Vaccinia protein that demonstrates biological activity as a Type I IFN receptor.

Vaccinia Virus Background

Vaccinia virus is a large, complex, enveloped virus, belonging to the Poxvirus family. Poxviruses are unique among DNA viruses, as they replicate only in the cytoplasm of the host cell, outside of the nucleus. Therefore, a large genome is required for encoding various enzymes and proteins involved in viral DNA replication and gene transcription. The close similarity of the Vaccinia virus to smallpox virus led to its use as a vaccination to prevent smallpox. Infection by Vaccinia in healthy individuals is generally asymptomatic, but may present with a mild fever and rash. It does, however, produce lasting immunity against other pox viruses, including smallpox. Vaccinia virus has therefore been used as a live vaccine against smallpox, and although now not widely used, it remains in use for healthcare workers, the US military, and researchers working with pox viruses. The use of the vaccine is associated with very rare but severe side-effects, primarily in immunocompromised individuals.

Vaccinia Antigens

We offer recombinant Vaccinia virus B18R protein, which contains two Ig-like C2-type domains and one Ig-like V-type domain. Vaccinia virus B18R exists in a soluble and membrane-bound form. As a type I IFN receptor, B18R counteracts the antiviral effects of host IFN-alpha/beta. The B18R protein also acts as a soluble IFN-alpha receptor and thus, inhibits the interaction between host IFN-alpha and its receptor. B18R was recently shown to enable increased cell viability during RNA transfection protocols, designed to convert human somatic donor cells into iPSCs.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Viral Lysates for Diagnostic Research

We've recently expanded our range of native viral cell lysates to complement our highly pure recombinant antigens. Here, we explain how our lysates are made and their uses in infectious disease R&D.What are viral lysates? Put simply, viral lysates are extracts of...

Cellular Receptors for Viral Entry

The most crucial step for viruses during human infection is recognition and entry into host cells. For this to happen, specific proteins on the virus capsid interact with those on the host cells' surface, through a 'lock-and-key'-type mechanism that mediates...

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 6 =

Live Customer Feedback